Home Online Features Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
Amit
Press Releases
Jubilant Therapeutics Inc.  
October 25, 2024

Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor

JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complexJBI-778 is a potential best-in-class, orally administered, brain penetrant inhibitor of PRMT5

logo salamanca press

Salamanca Press

email salamanca press
Local & Social